This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
Human medicines European public assessment report (EPAR): Blitzima, rituximab, D...
Appendix 1: Acceptable intakes established for N-nitrosamines
Human medicines European public assessment report (EPAR): Enyglid, repaglinide, ...
Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Pro...
Clinical Trials Information System (CTIS): training and support
Human medicines European public assessment report (EPAR): Vumerity, diroximel fu...
Questions and answers on implementation of the medical devices and in vitro diag...
Human medicines European public assessment report (EPAR): Quviviq, daridorexant,...
European Shortages Monitoring (ESMP) - Question and answer clinic for marketing ...
US president says Ross Ulbricht was victim of ‘weaponisation of government’
Nominee says he is entitled to 10% of proceeds if case against Merck’s Gardasil ...
Sector knocked by disappointing sales, an unexpected trial result and questions ...
The San Francisco-based start-up plans to get its first drug into trials this year
New deal is $1.4bn higher than previous one struck down by Supreme Court last year
US president threatens to double tax rates for foreign nationals and companies
People treated with amycretin lost up to 22% of their body weight after 36 weeks
FTSE’s most valuable company faces potential fine over suspected unpaid taxes in...
Drugmaker pins hopes on launch of new medicines but key point is to avoid re-tra...